Xiuzheng Pharmaceutical To Build Pharmaceutical Hub In Fujian
This article was originally published in PharmAsia News
Xiuzheng Pharmaceutical Group has signed an MOU with Yongchun county government to set up a production, R&D and sales base. This will be built upon Fujian Yongchun Pharmaceutical Factory's infrastructure, which it acquired last August. According to the agreement, Yongchun Pharmaceutical Factory will be Xiuzheng's pharmaceutical parent company in Fujian to control the group's drug production and distribution business in the southeast province. In addition, a logistics center will also be established, with Fujian as the hub to cover south, east and central China. Xiuzheng will inject RMB 300 million into Yongchun county and aims to hit RMB 3 billion annual production after completing the investment. (Click here for more - Chinese Language)
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.